860 related articles for article (PubMed ID: 16841178)
1. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional profiles of progestogen effects in the postmenopausal breast.
Wood CE; Register TC; Cline JM
Breast Cancer Res Treat; 2009 Mar; 114(2):233-42. PubMed ID: 18404370
[TBL] [Abstract][Full Text] [Related]
3. Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model.
Wood CE; Sitruk-Ware RL; Tsong YY; Register TC; Lees CJ; Cline JM
Menopause; 2007; 14(4):639-47. PubMed ID: 17224855
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of oral conjugated equine estrogens and micronized 17beta-estradiol on breast proliferation: a retrospective analysis.
Wood CE; Clarkson TB; Chen H; Veenstra TD; Xu X; Scott L; Cline JM
Menopause; 2008; 15(5):890-8. PubMed ID: 18520696
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
Seeger H; Rakov V; Mueck AO
Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy effects on social behavior and activity levels of surgically postmenopausal cynomolgus monkeys.
Shively CA; Wood CE; Register TC; Willard SL; Lees CJ; Chen H; Sitruk-Ware RL; Tsong YY; Cline JM
Psychoneuroendocrinology; 2007; 32(8-10):981-90. PubMed ID: 17768011
[TBL] [Abstract][Full Text] [Related]
7. Micronized progesterone and its impact on the endometrium and breast vs. progestogens.
Gompel A
Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT.
Dahmoun M; Odmark IS; Risberg B; Karlsson MG; Pavlenko T; Bäckström T
Maturitas; 2004 Oct; 49(2):114-23. PubMed ID: 15474755
[TBL] [Abstract][Full Text] [Related]
9. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.
Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A
Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598
[TBL] [Abstract][Full Text] [Related]
11. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
12. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
Seeger H; Wallwiener D; Mueck AO
Gynecol Endocrinol; 2008 Oct; 24(10):576-9. PubMed ID: 19012101
[TBL] [Abstract][Full Text] [Related]
13. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors.
Chen FP; Chien MH; Chen HY; Huang TS; Ng YT
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):365-73. PubMed ID: 24075375
[TBL] [Abstract][Full Text] [Related]
14. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
15. Estradiol and medroxyprogesterone acetate regulated genes in T47D breast cancer cells.
Mrusek S; Classen-Linke I; Vloet A; Beier HM; Krusche CA
Mol Cell Endocrinol; 2005 May; 235(1-2):39-50. PubMed ID: 15866426
[TBL] [Abstract][Full Text] [Related]
16. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
[TBL] [Abstract][Full Text] [Related]
17. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Seeger H; Wallwiener D; Mueck AO
Horm Metab Res; 2003 Feb; 35(2):76-80. PubMed ID: 12734785
[TBL] [Abstract][Full Text] [Related]
18. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells.
Purmonen S; Manninen T; Pennanen P; Ylikomi T
Oncol Rep; 2008 Jun; 19(6):1627-34. PubMed ID: 18497975
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
Werner HM; Franke HR; Vermes I
Climacteric; 2005 Sep; 8(3):294-9. PubMed ID: 16390761
[TBL] [Abstract][Full Text] [Related]
20. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells.
Schneck H; Ruan X; Seeger H; Cahill MA; Fehm T; Mueck AO; Neubauer H
Gynecol Endocrinol; 2013 Feb; 29(2):160-3. PubMed ID: 23116217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
